Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
A wildly profitable orphan-drug franchise priced like a melting ice cube—because a Delaware judge may decide when WAKIX goes generic.
Overview
Harmony Biosciences is a highly profitable, commercial-stage rare neurology company whose present-day business is almost entirely WAKIX (pitolisant) in the U.S. WAKIX is a first-in-class, FDA-approved H3 antagonist/inverse agonist for narcolepsy EDS and cataplexy (adult and pediatric), and it is uniquely non-scheduled—avoiding REMS/controlled-substance burdens that complicate legacy oxybate and stimulant therapies. Commercial execution has been exceptional: 2025 net product revenue reached $868.5M (+~21–22% YoY) with management expecting blockbuster status (> $1B) in 2026; active patients rose to ~8,500 by Q4 2025. The investment debate is a stark dichotomy: world-class cash generation and an efficient model versus existential IP vulnerability. Paragraph IV litigation—especially the unresolved AET Pharma case after a Feb 2026 bench trial—creates a binary risk of premature generic entry that could rapidly commoditize the sole revenue stream. In response, Harmony is pursuing aggressive lifecycle extensions (pitolisant GR/HD) and pipeline diversification (orexin-2 agonist BP1.15205; rare epilepsy EPX-100/200), attempting to evolve from a single-asset story into a diversified CNS/rare disease company before exclusivity erodes.